Cargando…
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the healthcare system...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197184/ https://www.ncbi.nlm.nih.gov/pubmed/35712723 http://dx.doi.org/10.3389/fphar.2022.881787 |
_version_ | 1784727349519974400 |
---|---|
author | Wu, Meiyu Qin, Shuxia Wang, Liting Tan, Chongqing Peng, Ye Zeng, Xiaohui Luo, Xia Yi, Lidan Wan, Xiaomin |
author_facet | Wu, Meiyu Qin, Shuxia Wang, Liting Tan, Chongqing Peng, Ye Zeng, Xiaohui Luo, Xia Yi, Lidan Wan, Xiaomin |
author_sort | Wu, Meiyu |
collection | PubMed |
description | Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the healthcare system perspective in China. Methods: Based on the KEYNOTE-590 trial, a Markov model was constructed to estimate the cost and effectiveness of pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively. Total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. One-way, probabilistic sensitivity analyses (PSA), and subgroup analyses were adapted to test the model robustness. Result: Compared with the placebo group, pembrolizumab group obtained an additional 1.05 QALY, but the cost was also increased by $121,478.76. The ICER was $115,391.84 per QALY gained, which was higher than the willingness-to-pay (WTP) of $31,304.31. The results of One-way sensitivity analyses showed that the ICER was sensitive to the hazard ratio of PFS and per cycle cost of pembrolizumab. At a WTP threshold of $31,304.31, the probability of pembrolizumab plus chemotherapy being cost-effective was 0%. Conclusion: From the perspective of China healthcare system, pembrolizumab plus chemotherapy as first-line treatment is not cost-effective for patients with advanced oesophageal cancer compared with placebo plus chemotherapy. |
format | Online Article Text |
id | pubmed-9197184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91971842022-06-15 Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer Wu, Meiyu Qin, Shuxia Wang, Liting Tan, Chongqing Peng, Ye Zeng, Xiaohui Luo, Xia Yi, Lidan Wan, Xiaomin Front Pharmacol Pharmacology Objective: Pembrolizumab plus chemotherapy is recommended as the first-line treatment for advanced oesophageal cancer. The objective of this study is to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer from the healthcare system perspective in China. Methods: Based on the KEYNOTE-590 trial, a Markov model was constructed to estimate the cost and effectiveness of pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively. Total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. One-way, probabilistic sensitivity analyses (PSA), and subgroup analyses were adapted to test the model robustness. Result: Compared with the placebo group, pembrolizumab group obtained an additional 1.05 QALY, but the cost was also increased by $121,478.76. The ICER was $115,391.84 per QALY gained, which was higher than the willingness-to-pay (WTP) of $31,304.31. The results of One-way sensitivity analyses showed that the ICER was sensitive to the hazard ratio of PFS and per cycle cost of pembrolizumab. At a WTP threshold of $31,304.31, the probability of pembrolizumab plus chemotherapy being cost-effective was 0%. Conclusion: From the perspective of China healthcare system, pembrolizumab plus chemotherapy as first-line treatment is not cost-effective for patients with advanced oesophageal cancer compared with placebo plus chemotherapy. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9197184/ /pubmed/35712723 http://dx.doi.org/10.3389/fphar.2022.881787 Text en Copyright © 2022 Wu, Qin, Wang, Tan, Peng, Zeng, Luo, Yi and Wan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wu, Meiyu Qin, Shuxia Wang, Liting Tan, Chongqing Peng, Ye Zeng, Xiaohui Luo, Xia Yi, Lidan Wan, Xiaomin Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title | Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title_full | Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title_fullStr | Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title_full_unstemmed | Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title_short | Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer |
title_sort | cost-effectiveness of pembrolizumab plus chemotherapy as first-line therapy for advanced oesophageal cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197184/ https://www.ncbi.nlm.nih.gov/pubmed/35712723 http://dx.doi.org/10.3389/fphar.2022.881787 |
work_keys_str_mv | AT wumeiyu costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT qinshuxia costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT wangliting costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT tanchongqing costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT pengye costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT zengxiaohui costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT luoxia costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT yilidan costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer AT wanxiaomin costeffectivenessofpembrolizumabpluschemotherapyasfirstlinetherapyforadvancedoesophagealcancer |